Aurobindo Pharma's Sterile Injectable Formulation line of Unit VIB, India has received the final approval for Ceftriaxone for Injection USP by USFDA

Aurobindo Pharma Limited is pleased to announce that the company has received final approvals from the US Food & Drug Administration (USFDA) for 2 ANDAs namely Ceftriaxone for Injection USP 250mg, 500mg, 1g, 2g and Ceftriaxone for Injection USP 10g pharmacy bulk pack. These are Cephalosporins products under the Anti-infective segment.

This is the first product approval of the Sterile Injectable Formulation line of Unit VI-B, situated in Hyderabad, India by USFDA. This is the Company's second sterile Injectable facility besides the facility of Cephazone JV in the State of California, USA. approved by USFDA.

Earlier the Unit VI-B Oral Cephalosporins Formulation line has been accorded the approval by USFDA

Aurobindo now has 72 ANDAs approved by the USFDA.

About Aurobindo Pharma Limited:

Aurobindo Pharma Limited (www.aurobindo.com), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company's robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics. The Company is marketing these products globally, in over 100 countries.

For further information, please contact:
Investor Relations
Aurobindo Pharma Limited
Reg Off: Plot No. 2, Maitrivihar, Ameerpet, Hyderabad
Phone: 040-66725000 / 66725401
Email: ir@aurobindo.com